Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine

Current Opinion in Anaesthesiology

Volumn 23, Issue 4, 2010, Pages 479-484

  Heeremans, Eleonora H ^a   Proost, Johannes H ^a   Eleveld, Douglas J ^a   Absalom, Anthony R ^a   Struys, Michel M R F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

nonlinear mixed effects modeling; pharmacodynamics; pharmacokinetics

Indexed keywords

ANESTHETIC AGENT; BUPIVACAINE; CAPSAICIN; CEFPIROME; DESFLURANE; HYPNOTIC AGENT; IBUPROFEN; ISOFLURANE; LEVOBUPIVACAINE; LINEZOLID; MIDAZOLAM; MORPHINE; MUSCLE RELAXANT AGENT; NAPROXEN; OPIATE; PROPOFOL; REMIFENTANIL; ROCURONIUM; ROPIVACAINE; SEVOFLURANE; SUGAMMADEX; TRAMADOL; VECURONIUM; ANALGESIC AGENT;

ANALGESIA; ANESTHESIA; BAYES THEOREM; BODY MASS; CLINICAL TRIAL; COMPARTMENT MODEL; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG UPTAKE; EPIDURAL ANESTHESIA; HUMAN; INFUSION PUMP; INFUSION SYSTEM; INTENSIVE CARE; LEAN BODY WEIGHT; MODEL; NEUROMUSCULAR BLOCKING; PAIN; PHARMACODYNAMICS; POPULATION RESEARCH; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; VISUAL ANALOG SCALE; AGE; AGED; ANIMAL; BODY WEIGHT; CHILD; CLINICAL PHARMACOLOGY; EPIDEMIOLOGY; ETHNIC GROUP; PHARMACOKINETICS; PHYSIOLOGY; POPULATION; STATISTICAL MODEL;

AGE FACTORS; AGED; ANALGESICS; ANESTHESIA; ANIMALS; BODY WEIGHT; CHILD; EPIDEMIOLOGIC METHODS; ETHNIC GROUPS; HUMANS; INTENSIVE CARE; MODELS, STATISTICAL; PAIN MANAGEMENT; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; POPULATION;

EID: 77954637098     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833a1d2f     Document Type: Review

References (62)

1. Kern SE, Stanski DR. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development. Clin Pharmacol Ther 2008; 84:153-157.
2. Avram MJ, Gupta DK, Atkinson AJ Jr. Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum. Clin Pharmacol Ther 2008; 84:3-6.
3. Levy G. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 1998; 34:323-333.
4. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26:294-305.
5. Proost JH, Schiere S, Eleveld DJ, et al. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique. Biopharm Drug Dispos 2007; 28:455-473.
6. Shafer SL, Struys MM. Mixed effect modeling in analgesia trials. Anesth Analg 2008; 107:9-10.
7. Anderson BJ, Holford NH. Leaving no stone unturned, or extracting blood from stone? Paediatr Anaesth 2010; 20:1-6.
8. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8:195-222.
9. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25:358-371.
10. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8:553-571.
11. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71:1344-1348.
12. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15:153-171.
13. Smith MK. Software for nonlinear mixed effects modelling: a review of several packages. Pharmaceut Statistics 2003; 2:69-75.
14. Absalom A, Struys MMRF. An overview of TCI & TIVA. 2nd ed. Gent: Academia Press; 2007.
15. Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology 2009; 110:1176-1181.
16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41:67-76.
17. Nunes CS, Ferreira DA, Antunes L, et al. Individual effect-site concentrations of propofol at return of consciousness are related to the concentrations at loss of consciousness and age in neurosurgical patients. J Clin Anesth 2009; 21:3-8.
18. McLeay SC, Morrish GA, Kirkpatrick CM, et al. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009; 26:1626-1634.
19. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58:119-133.
20. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997; 86:10-23.
21. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88:1170-1182.
22. Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999; 90:1502-1516.
23. James WPT. Research on obesity. London: Her Majesty's Stationery Office; 1976.
24. Coetzee JF. Total intravenous anaesthesia to obese patients: largely guesswork? Eur J Anaesthesiol 2009; 26:359-361.
25. Absalom AR, Mani V, De Smet T, et al. Pharmacokinetic models for propofol: defining and illuminating the devil in the detail. Br J Anaesth 2009; 103:26-37.
26. Lemmens HJ, Saidman LJ, Eger EI 2nd, et al. Obesity modestly affects inhaled anesthetic kinetics in humans. Anesth Analg 2008; 107:1864-1870.
27. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99:864-870.
28. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48:303-332.
29. Rigby-Jones AE, Priston MJ, Sneyd JR, et al. Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. Br J Anaesth 2007; 99:252-261.
30. Standing JF, Hammer GB, Sam WJ, et al. Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Paediatr Anaesth 2010; 20:7-18.
31. Chen L, Baker MD. Racial and ethnic differences in the rates of urinary tract infections in febrile infants in the emergency department. Pediatr Emerg Care 2006; 22:485-487.
32. Xu Z, Liu F, Yue Y, et al. C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial. Anesth Analg 2009; 108:478-483.
33. Minto CF, Schnider TW. Contributions of PK/PD modeling to intravenous anesthesia. Clin Pharmacol Ther 2008; 84:27-38.
34. Struys MM, Coppens MJ, De Neve N, et al. Influence of administration rate on propofol plasma-effect site equilibration. Anesthesiology 2007; 107:386-396.
35. Masui K, Kira M, Kazama T, et al. Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate. Anesthesiology 2009; 111:805-817.
36. Cortinez LI, Troconiz IF, Fuentes R, et al. The influence of age on the dynamic relationship between end-tidal sevoflurane concentrations and bispectral index. Anesth Analg 2008; 107:1566-1572.
37. Fuentes R, Cortinez LI, Struys MM, et al. The dynamic relationship between end-tidal sevoflurane concentrations, bispectral index, and cerebral state index in children. Anesth Analg 2008; 107:1573-1578.
38. Kreuer S, Bruhn J, Wilhelm W, et al. Comparative pharmacodynamic modeling of desflurane, sevoflurane and isoflurane. J Clin Monit Comput 2009; 23:299-305.
39. Olofsen E, Sleigh JW, Dahan A. Permutation entropy of the electroencephalogram: a measure of anaesthetic drug effect. Br J Anaesth 2008; 101:810-821.
40. Vuyk J, Lichtenbelt BJ, Olofsen E, et al. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. Anesth Analg 2009; 108:1522-1530.
41. Minto CF, Schnider TW, Short TG, et al. Response surface model for anesthetic drug interactions. Anesthesiology 2000; 92:1603-1616.
42. Short TG, Ho TY, Minto CF, et al. Efficient trial design for eliciting a pharmacokinetic- pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drugs. Anesthesiology 2002; 96:400-408.
43. Bouillon T, Bruhn J, Radu-Radulescu L, et al. Nonsteady state analysis of the pharmacokinetic interaction between propofol and remifentanil. Anesthesiology 2002; 97:1350-1362.
44. Struys MM, De Smet T, Mortier EP. Simulated drug administration: an emerging tool for teaching clinical pharmacology during anesthesiology training. Clin Pharmacol Ther 2008; 84:170-174.
45. Kelz MB, Eckenhoff RG. Does it add up? Anesth Analg 2008; 107:365-366.
46. Jenkins A, Lobo IA, Gong D, et al. General anesthetics have additive actions on three ligand gated ion channels. Anesth Analg 2008; 107:486-493.
47. Eger EI 2nd, Tang M, Liao M, et al. Inhaled anesthetics do not combine to produce synergistic effects regarding minimum alveolar anesthetic concentration in rats. Anesth Analg 2008; 107:479-485.
48. Shafer SL, Hendrickx JF, Flood P, et al. Additivity versus synergy: a theoretical analysis of implications for anesthetic mechanisms. Anesth Analg 2008; 107:507-524.
49. Hendrickx JF, Eger EI 2nd, Sonner JM, et al. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494-506.
50. Eger EI 2nd, Raines DE, Shafer SL, et al. Is a new paradigm needed to explain how inhaled anesthetics produce immobility? Anesth Analg 2008; 107:832-848.
51. Schumacher PM, Dossche J, Mortier EP, et al. Response surface modeling of the interaction between propofol and sevoflurane. Anesthesiology 2009; 111:790-804.
52. Ploeger BA, Smeets J, Strougo A, et al. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110:95-105.
53. Debiec J, Conell-Price J, Evansmith J, et al. Mathematical modeling of the pain and progress of the first stage of nulliparous labor. Anesthesiology 2009; 111:1093-1110.
54. Aasvang EK, Hansen JB, Malmstrom J, et al. The effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain: a double-blind, randomized, placebo-controlled study. Anesth Analg 2008; 107:282-291.
55. Zeidan A, Kassem R, Nahleh N, et al. Intraarticular tramadol-bupivacaine combination prolongs the duration of postoperative analgesia after outpatient arthroscopic knee surgery. Anesth Analg 2008; 107:292-299.
56. Sigtermans M, Dahan A, Mooren R, et al. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic- pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009; 111:892-903.
57. Bressolle F, Rochette A, Khier S, et al. Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. Br J Anaesth 2009; 102:390-399.
58. Abou Hammoud H, Simon N, Urien S, et al. Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis. Pain 2009; 144:139-146.
59. Gregoire N, Desfrere L, Roze JC, et al. Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. J Clin Pharmacol 2008; 48:1460-1468.
60. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851.
61. Roos JF, Lipman J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007; 33:781-788.
62. Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 2009; 49:1071-1078.